Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT03689855
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Trial of Ipatasertib in Combination With Atezolizumab
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 87
- Registration Number
- NCT03673787
- Locations
- 🇬🇧
Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT03647956
- Locations
- 🇭🇰
Department of Clinical Oncology, Hong Kong, Hong Kong
Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT03644823
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 107
- Registration Number
- NCT03637764
- Locations
- 🇺🇸
Investigational Site Number :8400007, Boston, Massachusetts, United States
🇺🇸Investigational Site Number :8400004, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400002, Houston, Texas, United States
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT03625141
- Locations
- 🇧🇷
Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil
🇧🇷Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, RS, Brazil
🇧🇷Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 25
- Registration Number
- NCT03620435
- Locations
- 🇨🇦
MUHC, Montreal, Quebec, Canada
Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT03616691
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 26
- Registration Number
- NCT03614949
- Locations
- 🇺🇸
Ohio State University - OSUMC - Wexner Medical Center, Hilliard, Ohio, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab
- Conditions
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 189
- Registration Number
- NCT03612791
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.